⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2797657 | 1.00 | — | — | |
| SCHEMBL15017679 | 0.62 | — | — | |
| SCHEMBL441570 | 0.62 | — | — | |
| SCHEMBL2252976 | 0.61 | — | — | |
| SCHEMBL14862826 | 0.60 | HTR6 (0.37) | — | |
| SCHEMBL16823392 | 0.60 | — | — | |
| SCHEMBL2360410 | 0.58 | — | — | |
| SCHEMBL9784554 | 0.58 | — | — | |
| SCHEMBL5741402 | 0.57 | — | — | |
| SCHEMBL4077331 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| WO-2024013209-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-01-18 | — | — | WO | claimed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| EP-3911640-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | claimed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | claimed |
| WO-2010124047-A1 | BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | WO | claimed |
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024013209-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-01-18 | — | — | WO | disclosed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911640-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-2424869-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010124047-A1 | BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |